Kyowa Hakko Kirin Licenses Potelligent To U.S. NKT Therapeutics
This article was originally published in PharmAsia News
Executive Summary
The U.S. subsidiary of the Japanese antibody-based drug maker Kyowa Hakko Kirin, BioWa, has licensed Potelligent to NKT Therapeutics